[HTML][HTML] Empagliflozin in heart failure with a preserved ejection fraction
Background Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, but their effects in …
heart failure in patients with heart failure and a reduced ejection fraction, but their effects in …
Empagliflozin in heart failure with a preserved ejection fraction
SD Anker, J Butler, G Filippatos… - New England …, 2021 - kyushu-u.elsevierpure.com
BACKGROUND Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization
for heart failure in patients with heart failure and a reduced ejection fraction, but their effects …
for heart failure in patients with heart failure and a reduced ejection fraction, but their effects …
Empagliflozin in heart failure with a preserved ejection fraction
EMPEROR-Preserved Trial … - … England Journal of …, 2021 - mayoclinic.elsevierpure.com
BACKGROUND Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization
for heart failure in patients with heart failure and a reduced ejection fraction, but their effects …
for heart failure in patients with heart failure and a reduced ejection fraction, but their effects …
[引用][C] Empagliflozin in Heart Failure with a Preserved Ejection Fraction
SD Anker, J Butler, G Filippatos, JP Ferreira, E Bocchi… - 2021 - repository.ubn.ru.nl
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization
for heart failure in patients with heart failure and a reduced ejection fraction, but their effects …
for heart failure in patients with heart failure and a reduced ejection fraction, but their effects …
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
SD Anker, J Butler, G Filippatos… - New England …, 2021 - cris.maastrichtuniversity.nl
BACKGROUNDSodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization
for heart failure in patients with heart failure and a reduced ejection fraction, but their effects …
for heart failure in patients with heart failure and a reduced ejection fraction, but their effects …
Empagliflozin in heart failure with a preserved ejection fraction.
SD Anker - Cardiology Research Review, 2021 - search.ebscohost.com
The EMPEROR-Preserved trial investigated the efficacy of the SGLT2 inhibitor empagliflozin
in patients with HFpEF. 5988 patients with class II-IV heart failure and LVEF > 40% were …
in patients with HFpEF. 5988 patients with class II-IV heart failure and LVEF > 40% were …
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
SD Anker, J Butler, G Filippatos, JP Ferreira… - New England Journal …, 2021 - hal.science
Background: Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, but their effects in …
heart failure in patients with heart failure and a reduced ejection fraction, but their effects in …
Empagliflozin in heart failure with a preserved ejection fraction
EMPEROR-Preserved Trial … - New England Journal …, 2021 - researchexperts.utmb.edu
BACKGROUND Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization
for heart failure in patients with heart failure and a reduced ejection fraction, but their effects …
for heart failure in patients with heart failure and a reduced ejection fraction, but their effects …
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
SD ANKER, J BUTLER, G FILIPPATOS… - … England Journal of …, 2021 - observatorio.fm.usp.br
BACKGROUND Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization
for heart failure in patients with heart failure and a reduced ejection fraction, but their effects …
for heart failure in patients with heart failure and a reduced ejection fraction, but their effects …
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
SD Anker, J Butler, G Filippatos, JP Ferreira, E Bocchi… - 2021 - muni.cz
BACKGROUND Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization
for heart failure in patients with heart failure and a reduced ejection fraction, but their effects …
for heart failure in patients with heart failure and a reduced ejection fraction, but their effects …